{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:09:06Z","timestamp":1793059746185,"version":"4.5.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.tips.2023.04.006","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T08:12:24Z","timestamp":1685175144000},"page":"442-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":236,"title":["Modulation of T cells by tryptophan metabolites in the kynurenine pathway"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5532-0031","authenticated-orcid":false,"given":"Trevor W.","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5473-5270","authenticated-orcid":false,"given":"Richard O.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2023.04.006_bb0005","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3389\/fimmu.2020.00624","article-title":"Regulation of T helper cell fate by TCR signal strength","volume":"11","author":"Bhattacharyya","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.006_bb0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fimmu.2020.00388","article-title":"IDO and kynurenine metabolites in peripheral and CNS disorders","volume":"11","author":"Huang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.006_bb0015","doi-asserted-by":"crossref","first-page":"1002004","DOI":"10.3389\/fnins.2022.1002004","article-title":"An integrated cytokine and kynurenine network as the basis of neuroimmune communication","volume":"16","author":"Stone","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.tips.2023.04.006_bb0020","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrd870","article-title":"Endogenous kynurenines as targets for drug discovery and development","volume":"1","author":"Stone","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2023.04.006_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/1178646917691938","article-title":"Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects","volume":"10","author":"Badawy","year":"2017","journal-title":"Int. J. Tryptophan Res."},{"key":"10.1016\/j.tips.2023.04.006_bb0030","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2023.04.006_bb0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4137\/IJTR.S4282","article-title":"On the biological importance of the 3-hydroxyanthranilic acid:anthranilic acid ratio","volume":"3","author":"Darlington","year":"2010","journal-title":"Int. J. Tryptophan Res."},{"key":"10.1016\/j.tips.2023.04.006_bb0040","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/s41467-018-04366-7","article-title":"Single cell analysis of kynurenine and System L amino acid transport in T cells","volume":"9","author":"Sinclair","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2023.04.006_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.949603","article-title":"Fine-tuning of regulatory T cells is indispensable for the metabolic steatosis-related hepatocellular carcinoma: a review","volume":"10","author":"Riaz","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.tips.2023.04.006_bb0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.molmed.2008.11.006","article-title":"TGF-\u03b2 and kynurenines as the key to infectious tolerance","volume":"15","author":"Belladonna","year":"2009","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tips.2023.04.006_bb0055","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3389\/fimmu.2017.01957","article-title":"Kynurenic acid: the Janus-faced role of an immunomodulatory tryptophan metabolite and its link to pathological conditions","volume":"8","author":"Wirthgen","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.006_bb0060","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s00018-019-03332-w","article-title":"Kynurenic acid and cancer: facts and controversies","volume":"77","author":"Walczak","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.tips.2023.04.006_bb0065","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nature13323","article-title":"Aryl hydrocarbon receptor control of a disease tolerance defence pathway","volume":"511","author":"Bessede","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.tips.2023.04.006_bb0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.tips.2023.04.006_bb0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/toxsci\/kfq024","article-title":"Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling","volume":"115","author":"DiNatale","year":"2010","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tips.2023.04.006_bb0080","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tips.2023.03.001","article-title":"GPR35: from enigma to therapeutic target","volume":"44","author":"Milligan","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2023.04.006_bb0085","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","article-title":"Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity","volume":"55","author":"Hezaveh","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.tips.2023.04.006_bb0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fphar.2015.00069","article-title":"The therapeutic potential of orphan GPCRs, GPR35 and GPR55","volume":"6","author":"Shore","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2023.04.006_bb0095","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0031-6997(25)00441-7","article-title":"Neuropharmacology of quinolinic and kynurenic acids","volume":"45","author":"Stone","year":"1993","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tips.2023.04.006_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103734","article-title":"Kynurenine induces T cell fat catabolism and has limited suppressive effects in vivo","volume":"74","author":"Siska","year":"2021","journal-title":"eBioMedicine"},{"key":"10.1016\/j.tips.2023.04.006_bb0105","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.cmet.2018.01.004","article-title":"Kynurenic acid and Gpr35 regulate adipose tissue energy homeostasis and inflammation","volume":"27","author":"Agudelo","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.tips.2023.04.006_bb0110","doi-asserted-by":"crossref","first-page":"eaaz7277","DOI":"10.1126\/sciimmunol.aaz7277","article-title":"Ahr\u2013Foxp3\u2013ROR\u03b3t axis controls gut homing of CD4+ T cells by regulating GPR15","volume":"5","author":"Xiong","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.tips.2023.04.006_bb0115","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1126\/science.aaa9420","article-title":"Individual intestinal symbionts induce a distinct population of ROR\u03b3+ regulatory T cells","volume":"349","author":"Sefik","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.tips.2023.04.006_bb0120","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1126\/science.aac4263","article-title":"The microbiota regulates type 2 immunity through ROR\u03b3t+ T cells","volume":"349","author":"Ohnmacht","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.tips.2023.04.006_bb0125","doi-asserted-by":"crossref","first-page":"eaal0180","DOI":"10.1126\/scisignal.aal0180","article-title":"A natural ligand for the orphan receptor GPR15 modulates lymphocyte recruitment to epithelia","volume":"10","author":"Suply","year":"2017","journal-title":"Sci. Signal."},{"key":"10.1016\/j.tips.2023.04.006_bb0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2500\/ajra.2016.30.4311","article-title":"Increased expression of the aryl hydrocarbon receptor in allergic nasal mucosa, contributing to chemokine secretion in nasal epithelium","volume":"30","author":"Kim","year":"2016","journal-title":"Am. J. Rhinol. Allergy"},{"key":"10.1016\/j.tips.2023.04.006_bb0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.humpath.2018.02.004","article-title":"Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer","volume":"75","author":"Ye","year":"2018","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.tips.2023.04.006_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114940","article-title":"Myricetin inhibits interferon-\u03b3-induced PD-L1 and IDO1 expression in lung cancer cells","volume":"197","author":"Chen","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2023.04.006_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.678999","article-title":"IDO1 expression in ovarian cancer induces PD-1 in T cells via aryl hydrocarbon receptor activation","volume":"12","author":"Amobi-McCloud","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.006_bb0150","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1240858","article-title":"The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas","volume":"5","author":"Sonner","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tips.2023.04.006_bb0155","article-title":"Immunosuppressive amino-acid catabolizing enzymes in multiple sclerosis","volume":"11","author":"Correale","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.006_bb0160","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1084\/jem.20020052","article-title":"Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites","volume":"196","author":"Terness","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tips.2023.04.006_bb0165","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/sj.cdd.4401073","article-title":"T cell apoptosis by tryptophan catabolism","volume":"9","author":"Fallarino","year":"2002","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.tips.2023.04.006_bb0170","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/TP.0000000000000856","article-title":"Indoleamine 2,3-dioxygenase transfected mesenchymal stem cells induce kidney allograft tolerance by increasing the production and function of regulatory T cells","volume":"99","author":"He","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.tips.2023.04.006_bb0175","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2019.01973","article-title":"Engagement of nuclear coactivator 7 by 3-hydroxyanthranilic acid enhances activation of aryl hydrocarbon receptor in immunoregulatory dendritic cells","volume":"10","author":"Gargaro","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.006_bb0180","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.7150\/thno.59841","article-title":"The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases","volume":"11","author":"Gan","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.tips.2023.04.006_bb0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41420-021-00561-6","article-title":"3-Hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness","volume":"7","author":"Gan","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.tips.2023.04.006_bb0190","doi-asserted-by":"crossref","first-page":"18619","DOI":"10.1073\/pnas.0709261104","article-title":"3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis","volume":"104","author":"Hayashi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2023.04.006_bb0195","doi-asserted-by":"crossref","first-page":"11674","DOI":"10.1073\/pnas.1921015117","article-title":"The PDK1\u2013FoxO1 signaling in adipocytes controls systemic insulin sensitivity through the 5-lipoxygenase-leukotriene B4 axis","volume":"117","author":"Hosooka","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2023.04.006_bb0200","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3389\/fimmu.2020.01861","article-title":"Differential roles of IDO1 and IDO2 in T and B cell inflammatory immune responses","volume":"11","author":"Merlo","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2023.04.006_bb0205","article-title":"TDO2 promotes the EMT of hepatocellular carcinoma through Kyn\u2013AhR pathway","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tips.2023.04.006_bb0210","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000523750","article-title":"Essential roles of TDO2 in gastric cancer: TDO2 is associated with cancer progression, patient survival, PD-L1 expression, and cancer stem cells","volume":"90","author":"Pham","year":"2022","journal-title":"Pathobiology"},{"key":"10.1016\/j.tips.2023.04.006_bb0215","doi-asserted-by":"crossref","first-page":"17950","DOI":"10.1021\/acs.jmedchem.1c01305","article-title":"Discovery of the first potent IDO1\/IDO2 dual inhibitors: a promising strategy for cancer immunotherapy","volume":"64","author":"He","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0220","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bcp.2019.07.011","article-title":"Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1\/IDO2\/TDO","volume":"168","author":"Feng","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2023.04.006_bb0225","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41392-019-0103-4","article-title":"Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn\u2013AhR\u2013AQP4 signaling pathway","volume":"5","author":"Du","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tips.2023.04.006_bb0230","doi-asserted-by":"crossref","first-page":"2005280","DOI":"10.1080\/2162402X.2021.2005280","article-title":"Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway","volume":"10","author":"Kim","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tips.2023.04.006_bb0235","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/ar2205","article-title":"Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice","volume":"9","author":"Szanto","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.tips.2023.04.006_bb0240","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/art.24446","article-title":"Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1\/Th17 cells in the joint in collagen-induced arthritis","volume":"60","author":"Criado","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tips.2023.04.006_bb0245","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.4049\/jimmunol.1001628","article-title":"IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis","volume":"185","author":"Yan","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2023.04.006_bb0250","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/hum.2009.217","article-title":"Amelioration of rat collagen-induced arthritis through CD4+ T cells apoptosis and synovial interleukin-17 reduction by indoleamine 2,3-dioxygenase gene therapy","volume":"22","author":"Chen","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.tips.2023.04.006_bb0255","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.molimm.2012.01.006","article-title":"An epigenetic mechanism for high, synergistic expression of indoleamine 2,3-dioxygenase 1 (IDO1) by combined treatment with zebularine and IFN-\u03b3: potential therapeutic use in autoimmune diseases","volume":"51","author":"Xue","year":"2012","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.tips.2023.04.006_bb0260","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2100939118","article-title":"Pharmacological modulation of T cell immunity results in long-term remission of autoimmune arthritis","volume":"118","author":"Huang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2023.04.006_bb0265","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1073\/pnas.1918215117","article-title":"Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation","volume":"117","author":"Mondanelli","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2023.04.006_bb0270","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","article-title":"IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression","volume":"182","author":"Sadik","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.tips.2023.04.006_bb0275","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood-2006-07-036210","article-title":"Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation","volume":"110","author":"Boulland","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.tips.2023.04.006_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142979","article-title":"IL4I1 is a novel regulator of M2 macrophage polarization that can inhibit T cell activation via L-tryptophan and arginine depletion and IL-10 production","volume":"10","author":"Yue","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2023.04.006_bb0285","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/eji.201041119","article-title":"IL4I1: an inhibitor of the CD8+ antitumor T-cell response in vivo","volume":"41","author":"Lasoudris","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.tips.2023.04.006_bb0290","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00251-022-01275-4","article-title":"IL4I1 enhances PD-L1 expression through JAK\/STAT signaling pathway in lung adenocarcinoma","volume":"75","author":"Zhu","year":"2023","journal-title":"Immunogenetics"},{"key":"10.1016\/j.tips.2023.04.006_bb0295","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3390\/jcm10102111","article-title":"IL4I1 is expressed by head-neck cancer-derived mesenchymal stromal cells and contributes to suppress T cell proliferation","volume":"10","author":"Mazzoni","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.tips.2023.04.006_bb0300","doi-asserted-by":"crossref","first-page":"1924500","DOI":"10.1080\/2162402X.2021.1924500","article-title":"What role for AHR activation in IL4I1-mediated immunosuppression ?","volume":"10","author":"Castellano","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tips.2023.04.006_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2013.01.031","article-title":"Prenatal inhibition of the tryptophan\u2013kynurenine pathway alters synaptic plasticity and protein expression in the rat hippocampus","volume":"1504","author":"Forrest","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.tips.2023.04.006_bb0310","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.neuint.2016.09.012","article-title":"Kynurenine pathway metabolism following prenatal KMO inhibition and in Mecp2+\/\u2013 mice, using liquid chromatography\u2013tandem mass spectrometry","volume":"100","author":"Forrest","year":"2016","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.tips.2023.04.006_bb0315","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/molecules27010273","article-title":"The kynurenine pathway and kynurenine 3-monooxygenase inhibitors","volume":"27","author":"Hughes","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.tips.2023.04.006_bb0320","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1002\/jcp.30876","article-title":"Kynurenine-3-monooxygenase (KMO): from its biological functions to therapeutic effect in diseases progression","volume":"237","author":"Chen","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.tips.2023.04.006_bb0325","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.drudis.2015.11.001","article-title":"Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitors","volume":"21","author":"Smith","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tips.2023.04.006_bb0330","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1021\/jm970467t","article-title":"Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase","volume":"40","author":"R\u00f6ver","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0335","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2174\/0929867324666170502123114","article-title":"Major developments in the design of inhibitors along the kynurenine pathway","volume":"24","author":"Jacobs","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108055","article-title":"Recent advances in clinical trials targeting the kynurenine pathway","volume":"236","author":"Pires","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tips.2023.04.006_bb0345","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.biopsych.2016.12.011","article-title":"Adaptive and behavioral changes in kynurenine 3-monooxygenase knockout mice: relevance to psychotic disorders","volume":"82","author":"Erhardt","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.tips.2023.04.006_bb0350","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.3390\/cells9061564","article-title":"Kynurenines in the pathogenesis of multiple sclerosis: therapeutic perspectives","volume":"9","author":"Biernacki","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.tips.2023.04.006_bb0355","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-4658.2012.08485.x","article-title":"Quinolinic acid, the inescapable neurotoxin","volume":"279","author":"Guillemin","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.tips.2023.04.006_bb0360","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.neuropharm.2016.03.024","article-title":"Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases","volume":"112","author":"Lovelace","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2023.04.006_bb0365","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3389\/fphar.2019.00452","article-title":"Quinolinic acid and nuclear factor erythroid 2-related factor 2 in depression: role in neuroprogression","volume":"10","author":"Bansal","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2023.04.006_bb0370","doi-asserted-by":"crossref","first-page":"9459","DOI":"10.1021\/acs.jpca.1c05397","article-title":"Computational survey of recent experimental developments in the hydroxylation mechanism of kynurenine 3-monooxygenase","volume":"125","author":"\u00d6zk\u0131l\u0131\u00e7","year":"2021","journal-title":"J. Phys. Chem. A"},{"key":"10.1016\/j.tips.2023.04.006_bb0375","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.3390\/molecules26113314","article-title":"Pharmacophore-based virtual screening of novel competitive inhibitors of the neurodegenerative disease target kynurenine-3-monooxygenase","volume":"26","author":"Gotina","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.tips.2023.04.006_bb0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0210-x","article-title":"Kynurenine 3-monooxygenase is a critical regulator of renal ischemia-reperfusion injury","volume":"51","author":"Zheng","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.tips.2023.04.006_bb0385","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1021\/acs.jmedchem.7b00055","article-title":"Development of a series of kynurenine 3-monooxygenase inhibitors leading to a clinical candidate for the treatment of acute pancreatitis","volume":"60","author":"Walker","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0390","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.expneurol.2016.05.005","article-title":"The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington\u2019s disease","volume":"282","author":"Beaumont","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.tips.2023.04.006_bb0395","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2174\/187152710793237430","article-title":"Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington\u2019s disease","volume":"9","author":"Thevandavakkam","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.tips.2023.04.006_bb0400","first-page":"1416","article-title":"Gram-scale preparation of cannflavin A from hemp (Cannabis sativa L.) and its inhibitory effect on tryptophan catabolism enzyme kynurenine-3-monooxygenase","volume":"11","author":"Puopolo","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.tips.2023.04.006_bb0405","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1007\/s00213-014-3452-2","article-title":"Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats","volume":"231","author":"Pocivavsek","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2023.04.006_bb0410","doi-asserted-by":"crossref","first-page":"2055703","DOI":"10.1080\/2162402X.2022.2055703","article-title":"Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism","volume":"11","author":"Yang","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tips.2023.04.006_bb0415","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/13543776.2016.1189531","article-title":"Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012\u20132015)","volume":"26","author":"Z\u00e1dori","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.tips.2023.04.006_bb0420","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/14756366.2018.1480614","article-title":"Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation","volume":"34","author":"Xu","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0425","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1021\/acs.jmedchem.0c01968","article-title":"Azole-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"64","author":"R\u00f6hrig","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113071","article-title":"Diverse chemical space of indoleamine-2,3-dioxygenase 1 (Ido1) inhibitors","volume":"211","author":"Singh","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0435","doi-asserted-by":"crossref","first-page":"9421","DOI":"10.1021\/acs.jmedchem.5b00326","article-title":"Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"58","author":"R\u00f6hrig","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0440","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1080\/14756366.2022.2089665","article-title":"Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"37","author":"R\u00f6hrig","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0445","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.3390\/ijms23073981","article-title":"Critical assessment of a structure-based screening campaign for IDO1 inhibitors: tips and pitfalls","volume":"23","author":"Mammoli","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2023.04.006_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104815","article-title":"The ups, downs and new trends of IDO1 inhibitors","volume":"110","author":"Chen","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0455","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/cmdc.202100446","article-title":"The [1,2,4]triazolo[4,3-a]pyridine as a new player in the field of IDO1 catalytic holo-inhibitors","volume":"16","author":"Fallarini","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.tips.2023.04.006_bb0460","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1535-7163.MCT-20-0251","article-title":"Preclinical characterization of linrodostat mesylate, a novel, potent, and selective oral indoleamine 2,3-dioxygenase 1 inhibitor","volume":"20","author":"Balog","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2023.04.006_bb0465","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1369\/0022155412458926","article-title":"Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis","volume":"60","author":"Fukunaga","year":"2012","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.tips.2023.04.006_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.940704","article-title":"Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors","volume":"13","author":"Hou","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2023.04.006_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127744","article-title":"Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors","volume":"33","author":"Steeneck","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2023.04.006_bb0480","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1021\/acsmedchemlett.1c00236","article-title":"Conformational-analysis-guided discovery of 2,3-disubstituted pyridine IDO1 inhibitors","volume":"12","author":"Cherney","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.tips.2023.04.006_bb0485","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.bmc.2019.03.005","article-title":"Design, synthesis and biological evaluation of 2,5-dimethylfuran-3-carboxylic acid derivatives as potential IDO1 inhibitors","volume":"27","author":"Yang","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0490","doi-asserted-by":"crossref","first-page":"8784","DOI":"10.1021\/acs.jmedchem.9b00942","article-title":"Inhibition mechanisms of indoleamine 2,3-dioxygenase 1 (IDO1)","volume":"62","author":"R\u00f6hrig","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0495","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.bbrc.2017.04.061","article-title":"Structural insights into the binding mechanism of IDO1 with hydroxylamidine based inhibitor INCB14943","volume":"487","author":"Wu","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2023.04.006_bb0500","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ejmech.2016.12.029","article-title":"Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): probing the active site\u2013inhibitor interactions","volume":"126","author":"Tomek","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0505","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1021\/acs.biochem.7b00586","article-title":"The binding mode of N-hydroxyamidines to indoleamine 2,3-dioxygenase 1 (IDO1)","volume":"56","author":"R\u00f6hrig","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.tips.2023.04.006_bb0510","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202209374","article-title":"Identification of a novel pseudo-natural product type IV IDO1 inhibitor chemotype","volume":"61","author":"Davies","year":"2022","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.tips.2023.04.006_bb0515","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/ph14030265","article-title":"Novel selective IDO1 inhibitors with isoxazolo[5,4-d]pyrimidin-4(5H)-one scaffold","volume":"14","author":"Dol\u0161ak","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.tips.2023.04.006_bb0520","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a Phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tips.2023.04.006_bb0525","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acs.jmedchem.9b01386","article-title":"Bifunctional naphthoquinone aromatic amide-oxime derivatives exert combined immunotherapeutic and antitumor effects through simultaneous targeting of indoleamine-2,3-dioxygenase and signal transducer and activator of transcription 3","volume":"63","author":"Huang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0530","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/jlcr.3263","article-title":"Synthesis of [18F] 4-amino-N-(3-chloro-4-fluorophenyl)-N\u2032-hydroxy-1,2,5-oxadiazole-3-carboximidamide (IDO5L): a novel potential PET probe for imaging of IDO1 expression","volume":"58","author":"Huang","year":"2015","journal-title":"J. Labelled Comp. Radiopharm."},{"key":"10.1016\/j.tips.2023.04.006_bb0535","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/cmdc.201700666","article-title":"Improving the potency of cancer immunotherapy by dual targeting of IDO1 and DNA","volume":"13","author":"Fang","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.tips.2023.04.006_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104401","article-title":"Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor","volume":"105","author":"Fan","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0545","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/acsmedchemlett.7b00487","article-title":"Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase (HDAC) dual inhibitors","volume":"9","author":"Fang","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.tips.2023.04.006_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103463","article-title":"Identification of inhibitors of the immunosuppressive enzyme IL4I1","volume":"94","author":"Presset","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0555","first-page":"A423","article-title":"Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme interleukin 4 (IL-4)-induced gene 1 (IL4I1)","volume":"8","author":"MacKinnon","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tips.2023.04.006_bb0560","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/ejn.12535","article-title":"Prenatal inhibition of the kynurenine pathway leads to structural changes in the hippocampus of adult rat offspring","volume":"39","author":"Khalil","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.tips.2023.04.006_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113631","article-title":"Design, synthesis and biological evaluation of exiguamine A analogues as IDO1 inhibitors","volume":"223","author":"Dong","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128115","article-title":"Discovery of N-(6-(5-fluoro-2-(piperidin-1-yl)phenyl)pyridazin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)methanesulfonamide as a brain-permeable and metabolically stable kynurenine monooxygenase inhibitor","volume":"44","author":"Tsuboi","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2023.04.006_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.854965","article-title":"Novel 1,2,3-triazole erlotinib derivatives as potent IDO1 inhibitors: design, drug-target interactions prediction, synthesis, biological evaluation, molecular docking and ADME properties studies","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2023.04.006_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128373","article-title":"Discovery of novel IDO1 inhibitors targeting the protein\u2019s apo form through scaffold hopping from holo-IDO1 inhibitor","volume":"52","author":"Wu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2023.04.006_bb0585","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1021\/acsmedchemlett.1c00265","article-title":"Utilization of metabolite identification and structural data to guide design of low-dose IDO1 inhibitors","volume":"12","author":"Hopkins","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.tips.2023.04.006_bb0590","doi-asserted-by":"crossref","first-page":"11302","DOI":"10.1021\/acs.jmedchem.1c00679","article-title":"Discovery of IACS-9779 and IACS-70465 as potent inhibitors targeting indoleamine 2,3-dioxygenase 1 (IDO1) apoenzyme","volume":"64","author":"Hamilton","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128314","article-title":"Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold","volume":"49","author":"Yu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2023.04.006_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128214","article-title":"SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors","volume":"47","author":"Yu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2023.04.006_bb0605","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1021\/acsmedchemlett.7b00488","article-title":"Identification of potent indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors based on a phenylimidazole scaffold","volume":"9","author":"Brant","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.tips.2023.04.006_bb0610","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/cmdc.202100107","article-title":"A series of 2-((1-phenyl-1H-imidazol-5-yl)methyl)-1H-indoles as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"16","author":"Zheng","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.tips.2023.04.006_bb0615","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s10822-021-00386-6","article-title":"Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays","volume":"35","author":"Ge","year":"2021","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.tips.2023.04.006_bb0620","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1080\/14756366.2020.1765165","article-title":"Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo","volume":"35","author":"Ge","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0625","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.2174\/1871520620666200604121225","article-title":"Design, synthesis and biological evaluation of novel 1,2,5-oxadiazol-3-carboximidamide derivatives as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"20","author":"Xia","year":"2020","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0630","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.579024","article-title":"Discovery of icotinib-1,2,3-triazole derivatives as IDO1 inhibitors","volume":"11","author":"Mao","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2023.04.006_bb0635","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1021\/acs.jmedchem.9b01809","article-title":"Discovery of highly potent benzimidazole derivatives as indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors: from structure-based virtual screening to in vivo pharmacodynamic activity","volume":"63","author":"Serafini","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0640","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/molecules25061447","article-title":"Design, synthesis and biological evaluation of phenyl urea derivatives as IDO1 inhibitors","volume":"25","author":"Zhou","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.tips.2023.04.006_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126901","article-title":"Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"30","author":"Kong","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2023.04.006_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103356","article-title":"Design, synthesis and biological evaluation of bicyclic carboxylic acid derivatives as IDO1 inhibitors","volume":"94","author":"Cai","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0655","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejmech.2019.06.037","article-title":"Design, synthesis and antitumor study of a series of N-cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"179","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0660","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ejmech.2018.08.013","article-title":"Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors","volume":"157","author":"Pan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127963","article-title":"Discovery of 5-(N-hydroxycarbamimidoyl) benzofuran derivatives as novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"40","author":"Jung","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2023.04.006_bb0670","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1016\/j.bmcl.2016.07.031","article-title":"1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2)","volume":"26","author":"R\u00f6hrig","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2023.04.006_bb0675","doi-asserted-by":"crossref","first-page":"14348","DOI":"10.1021\/acs.jmedchem.2c00263","article-title":"Discovery of the first selective IDO2 inhibitor as novel immunotherapeutic avenues for rheumatoid arthritis","volume":"65","author":"He","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0680","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/acsmedchemlett.7b00427","article-title":"Aminoisoxazoles as potent inhibitors of tryptophan 2,3-dioxygenase 2 (TDO2)","volume":"9","author":"Pei","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.tips.2023.04.006_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114524","article-title":"Dual-target inhibitors of indoleamine 2,3 dioxygenase 1 (Ido1): a promising direction in cancer immunotherapy","volume":"238","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111985","article-title":"Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1\/TDO dual inhibitors","volume":"188","author":"Cui","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0695","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.bmc.2019.02.014","article-title":"4,6-Substituted-1H-indazoles as potent IDO1\/TDO dual inhibitors","volume":"27","author":"Yang","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112703","article-title":"Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO)","volume":"207","author":"Pan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2023.04.006_bb0705","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/ph14121291","article-title":"Heterocyclic cathinones as inhibitors of kynurenine aminotransferase II \u2013 design, synthesis, and evaluation","volume":"14","author":"Mary\u0161ka","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.tips.2023.04.006_bb3000","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127060","article-title":"Discovery of sulfonamides and 9-oxo-2,8-diazaspiro[5,5]undecane-2-carboxamides as human kynurenine aminotransferase 2 (KAT2) inhibitors","volume":"30","author":"Kalliokoski","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614723000895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614723000895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:15:05Z","timestamp":1759050905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614723000895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":142,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0165614723000895"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2023.04.006","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulation of T cells by tryptophan metabolites in the kynurenine pathway","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2023.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}